04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
21:44 , Mar 22, 2019 |  BC Extra  |  Clinical News

After aducanumab failure, Eisai to test another anti-amyloid mAb

With the announcement that Eisai plans to start yet another Phase III trial of an anti-amyloid candidate, Alzheimer's disease researcher Rudolph Tanzi told BioCentury he wouldn't enroll any more AD patients in trials of therapies...
00:43 , Mar 22, 2019 |  BioCentury  |  Finance

Biogen's lead balloon

Biogen took a 29% haircut to $226.88 on Thursday following its decision to discontinue the Phase III ENGAGE and EMERGE trials of aducanumab for Alzheimer’s disease. The company's stock price has been dragged down 48%...
12:30 , Mar 21, 2019 |  BC Extra  |  Clinical News

Biogen, Eisai discontinuing aducanumab studies in AD

Biogen and Eisai said aducanumab is unlikely to meet the primary endpoints of two Phase III trials to treat early Alzheimer's disease, joining a long list of failed mAbs against β amyloid and putting more...
14:41 , Mar 4, 2019 |  BC Extra  |  Company News

Biogen to acquire ophthalmology gene therapy play Nightstar

Gene therapy platforms continue to capture the interest of large biopharma, with Biogen the latest to announce a deal. The bellwether said early Monday that it will acquire ophthalmology gene therapy company Nightstar for $877...
01:11 , Feb 1, 2019 |  BC Week In Review  |  Clinical News

Roche stops crenezumab trials in early Alzheimer's for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback on Jan. 30 after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc....
00:51 , Feb 1, 2019 |  BC Week In Review  |  Company News

Spinraza sales lift Biogen revenues

Biogen Inc. (NASDAQ:BIIB) said Jan. 29 that growing sales of spinal muscular atrophy therapy Spinraza nusinersen helped the company to a 10% increase in 2018 revenues. The company also disclosed plans in its 2018 earnings...
23:47 , Jan 30, 2019 |  BC Extra  |  Clinical News

Roche stops crenezumab trials in early Alzheimer’s for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback Wednesday after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc. unit has...
01:20 , Jan 30, 2019 |  BC Extra  |  Company News

Spinraza sales lift Biogen revenues

Biogen Inc. (NASDAQ:BIIB) said Tuesday that growing sales of spinal muscular atrophy therapy Spinraza nusinersen helped the company to a 10% increase in 2018 revenues. The company also disclosed plans in its 2018 earnings to...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...